AKAlice Ketchaji

Alice Ketchaji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alice Ketchaji has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Confirmed virological failure following enhanced adherence counseling among virally unsuppressed children and adolescents on dolutegravir-based versus other regimens: Evidence from a cohort analysis in Cameroon

    by Yagai Bouba, Aude Christelle Ka’E, Davy-Hyacinthe Anguechia Gouissi, Cynthia Ayafor, Dominik Tameza Guebiapsi, Samuel Martin Sosso, Rachel Simo Kamgaing, Suzie Ndiang Tetang, Suzane Essamba, Nelly Kamgaing, et al.

    Achieving and maintaining viral suppression (VS) in pediatric populations remain suboptimal in low- and middle-income countries (LMICs), calling for the optimized management approaches. We compared the rate of confirmed virological failure (cVF) and associated factors among virally non-suppressed (VnS) children and adolescents after enhanced adherence counseling (EAC) on dolutegravir-based versus other regimens. A multicentre and prospective cohort study was conducted among ART-experienced children (P = .026. According to ART-regimen, cVF rate was 29.3% in those receiving TDF/3TC/DTG versus 43.5% for ABC/3TC + ATV/r/LPV/r and 25.6% for ABC/3TC + DTG, P = .007. Regarding anchor-drugs, cVF with DTG, EFV and ATV/r/LPV/r was 28.1%, 48.4% and 49.2%, respectively, P = .007. Interestingly, 13.2% of participants with VS had detectable low-level viremia (400–999 copies/mL), with 5.8%, 7.7% and 12.9% being observed in those receiving DTG, ATV/r/LPV/r, and EFV/NVP-based regimen, respectively, P = .013. Only anchor-drug was found to be a predictor of cVF. Compared to those receiving DTG-based regimens, ART based on ATV/LPV/r (aOR [95% CI]: 0.298 [0.132–0.72], P = .004) or EFV/NVP (aOR [95% CI]: 0.401 [0.163–0.983], P = .046) was significantly less likely to achieve VS. About 40% of Cameroonian children/adolescents with VnS experience cVF, which is indicative that EAC significantly contributes to viral re-suppression (60%), especially with DTG-based regimens. Thus, implementing a strategy that couples DTG-transition with EAC-interventions would contribute substantially to efforts in eliminating pediatric AIDS in LMICs.


  • Open Access

    The impact of short message service reminders or peer home visits on adherence to antiretroviral therapy and viral load suppression among HIV-Infected adolescents in Cameroon: a randomized controlled trial

    by Alice Ketchaji, Joseph Fokam, Felix Assah, Francis Ateba, Martial Lantche Wandji, Joelle Nounouce Bouba Pamen, Godfroy Rostant Pokam Djoko, Cedric Dylan Nana Seugnou, Emmanuel Kah, Alain Fouda Atangana, et al.

    Adherence to antiretroviral therapy (ART) and viral load suppression (VLS) constitute one of the key challenges to control human immunodeficiency virus (HIV), especially during adolescence. This trial aimed at assessing the impact of short message services (SMS) or peer home visits (PHV) on adherence to ART and VL suppression among adolescents living with HIV (ALWHIV) in Cameroon. A randomized controlled trial (RCT) was conducted from July 2018 to February 2019 at the Mother and Child Center of the Chantal Biya Foundation in Yaounde. Eligible ALWHIV (15–19 years), with a fully disclosed HIV status, with availability of phone and guardian’s consent, were randomly assigned to receive either daily SMS or bi-weekly PHV for a six-months period. The control-group received standard of care according to the national guidelines. Study investigators and participants were not blinded to the interventions group allocation, and no adverse events or side effects were observed. Adjusted logistic regression was used to assess the impact of interventions on outcomes. The study was approved by The Pan-African Clinical Trials Registry with PACTR201904582515723 at ( www.pactr.org ). Adherence to ART increased in the PHV (aRR: 4.3; 95% CI: 2.2–8.3; p < 0.001) and SMS (aRR: 3.1, 95% CI: 2.1–5.3; p < 0.001) groups compared to the control-group. Likewise, VL suppression was higher in PHV (aRR: 2.1; 95% CI: 1.9–7.5 p < 0.001) and SMS (aRR: 3.2; 95% CI: 1.8–5.4; p < 0.001) groups compared to the control-group. Based on CI, both interventions showed similar benefits on improving adherence and VLS. Among ALHIV, SMS or PHV contribute substantially to improving adherence and VL suppression among ALWHIV. Implementing such strategies would support efforts in eliminating pediatric AIDS in low- and middle-income countries.


  • Open Access

    Factors influencing direct payment exemption in the user fee elimination project in the Far North of Cameroon

    by Sali Aristide Dama, Alice Ketchaji, Dorcas Kamguem Keng, Laura Ladouce Yanguem, Godfroy Rostant Pokam Djoko

    On January 1, 2020, the State of Cameroon instituted a policy to eliminate direct payments by people living with human immunodeficiency virus (PLHIV). However, limited data are available on the implementation of this policy. This study aims to identify the determinants of the improper implementation of this policy by healthcare providers. To this end, a cross-sectional study was conducted with 164 medical and paramedical staff involved in the care of PLHIV. Data were collected using a Google Forms questionnaire and administered in health facility forums. Determinants were assessed using multiple logistic regression analysis. The study found that the job profile of a doctor or pharmacist (odds ratio adjusted [AOR] = 9.64 [95% confidence interval (CI): 2.32 – 44.09]; p = 0.002), access to policy guidelines (AOR = 2.81 [95% CI: 1.02 – 7.86]; p = 0.045), perception of the policy’s impact on quality of care (AOR = 4.26 [95% CI: 0.79 – 26.95]; p = 0.034), and the context of working in a system in which the policy is partially effective (AOR = 4.0 [95% CI: 1.53 – 11.08]; p = 0.005) significantly increased the chances of improper practices related to policy implementation. Awareness-raising and capacity-building strategies must be developed to policy implementation by healthcare providers in Cameroon. The policy of “user fees elimination” marks the first step toward universal health coverage, and this study also provides a basis for reflection to facilitate its optimal implementation.


  • Open Access

    Factors associated with cervical cancer screening among women attending gynecological consultations at the Maroua Regional Hospital, Cameroon

    by Verance Carline Kegha Ngodem, Alice Ketchaji, Protais Cédric Mouenbori Sawi, Manuela Tchinda Magne, Thierry Malex Nwafo Ndjimafo, Laura Ladouce Yanguem, Godfroy Rostant Pokam Djoko

    This study aimed to assess the factors associated with cervical cancer screening at the Maroua Regional Hospital. A cross-sectional study was conducted among 376 women aged ≥25 years attending gynecological consultations at the Maroua Regional Hospital between February and May 2023. Data were collected through a structured questionnaire survey. These factors were evaluated through multiple logistic regression analyses, and associations were established by calculating the odds ratios, confidence intervals, and p-values. A total of 376 women were interviewed. Their mean age was 39.21 ± 10.45 years. Of the 376 women, 9.3% had already been screened for cervical cancer. Results of multivariate analyses indicated that age ≥45 years, belief that every woman should be screened at age 25 years, perceived need for frequent screening, use of screening as a preventive measure, and having had first intercourse before age 15 years or between ages 15 and 20 years significantly increased the likelihood of having been screened. Strategies need to be developed to improve access to cervical cancer screening services in Cameroon by strengthening existing screening programs and effectively implementing campaigns to improve access to screening services.


  • Open Access

    Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study

    by Joseph Fokam, Yagai Bouba, Rogers Awoh Ajeh, Dominik Tameza Guebiapsi, Suzane Essamba, Albert Franck Zeh Meka, Ebiama Lifanda, Rose Armelle Ada, Liman Yakouba, Nancy Barbara Mbengono, et al.

    Mortality in children accounts for 15% of all AIDS-related deaths globally, with a higher burden among Cameroonian children (25%), likely driven by poor virological response. We sought to evaluate viral suppression (VS) and its determinants in a nationally representative paediatric and young adult population receiving antiretroviral therapy (ART). A cross-sectional and multicentric study was conducted among Cameroonian children (p < 0.001. VS was 85.1% on a DTG-based regimen versus 80.0% on efavirenz/nevirapine and 65.6% on lopinavir/ritonavir or atazanavir/ritonavir. VS was higher in females versus males (85.8% versus 78.2%, p < 0.001). The VS rate remained stable around 85% at 12 and 24 months but dropped to about 80% at 36 months after ART initiation, p < 0.009. Independent predictors of non-VS were younger age, longer ART duration (>36 months), backbone drug (non-TDF/3TC) and anchor drug (non-DTG based). In this Cameroonian paediatric population with varying levels of transition to DTG, overall VS remains below the 95% targets. Predictors of non-VS are younger age, non-TDF/3TC- and non-DTG-based regimens. Thus, efforts toward eliminating paediatric AIDS should prioritise the transition to a DTG-based regimen in this new ART era.


  • Open Access

    Evidence On Viral Suppression Supports Scaling-Up Transition To Dolutegravir-Based Regimens In Pediatric Populations In Cameroon: A Multicentre Baseline Assessment For The Cipher-Adola Study

    by Joseph Fokam, Yagai Bouba, Rogers Awoh Ajeh, Dominik Tameza Guebiapsi, Suzane Essamba, Albert Franck Zeh Meka, Ebiama Lifanda, Rose Armelle Ada, Yakouba Liman, Nancy Barbara Mbengono, et al.

    Mortality in children accounts for 15% of all AIDS-related deaths globally, with a higher burden among Cameroonian children (25%), likely due to poor virological response. We sought to evaluate viral suppression (VS) and its determinants in a nationally representative paediatric and young adult population receiving antiretroviral therapy (ART). A cross-sectional and multicentric study was conducted among Cameroonian children (

  • Open Access

    Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics

    by Joseph PhD Fokam, Alex Durand Nka, Flore Yollande Bmls Mamgue Dzukam, Jeremiah Bmls Efakika Gabisa, Yagai Bouba, Michel Carlos Msc Tommo Tchouaket, Aude Christelle Msc Ka’e, Ezechiel Ngoufack Jagni Semengue, Desire Msc Takou, Sylvie Moudourou, et al.

    This study aimed to compare viral suppression (VS) between children, adolescents, and adults in the frame of transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in the Cameroonian context. A comparative cross-sectional study was conducted from January 2021 through May 2022 amongst ART-experienced patients received at the Chantal BIYA International Reference Centre in Yaounde-Cameroon, for viral load (VL) monitoring. VS was defined as VL < 1000 copies/mL and viral undetectability as VL < 50 copies/mL. Chi-square and multivariate binary logistic regression models were used to identify factors associated with VS. Data were analyzed using SPSS v.20.0 (SPSS Inc., Chicago, Illinois), with P < .05 considered significant. A total of 9034 patients (72.2% females) were enrolled. In all, there were 8585 (95.0%) adults, 227 (2.5%) adolescents, and 222 (2.5%) children; 1627 (18.0%) were on non-nucleoside reverse transcriptase-based, 290 (3.2%) on PI-based, and 7117 (78.8%) on DTG-based ART. Of those on DTG-based ART, only 82 (1.2%) were children, 138 (1.9%) adolescents, and 6897 (96.9%) adults. Median (interquartile range) duration on ART was 24 (12–72) months (24 months on Tenofovir + Lamivudine + Dolutegravir [TLD], 36 months on other first lines, and 84 months on protease inhibitors boosted with ritonavir-based regimens). Overall, VS was 89.8% (95% confidence interval: 89.2–90.5) and viral undetectability was 75.7% (95% confidence interval: 74.8–76.7). Based on ART regimen, VS on Non-nucleoside reverse transcriptase-based, protease inhibitors boosted with ritonavir-based, and DTG-based therapy was respectively 86.4%, 59.7%, and 91.8%, P < .0001. Based on ART duration, VS was respectively 51.7% (≤24 months) versus 48.3% (≥25 months), P < .0001. By gender, VS was 90.9% (5929) in females versus 87.0% (2183) in males, P < .0001; by age-range, VS moved from 64.8% (144) in children, 74.4% (169) adolescents, to 90.8% (7799) adults, P < .0001. Following multivariate analysis, VS was associated with adulthood, female gender, TLD regimens, and combination antiretroviral therapy duration > 24 months (P < .05). In Cameroon, ART response indicates encouraging rates of VS (about 9/10) and viral undetectability (about 3/4), driven essentially by access to TLD based regimens. However, ART response was very poor in children, underscoring the need for scaling-up pediatric DTG-based regimens.